Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

Wedbush analyst David Nierengarten has maintained an 'Outperform' rating on Disc Medicine (NASDAQ: IRON) and increased the price target from $100 to $110. This adjustment reflects positive expectations for the company's performance in the market.